Ironwood Pharmaceuticals Inc IRWD:NASDAQ

Last Price$12.41Cboe Real-Time Last Sale as of 12:24PM ET 1/23/19
Cboe Real-Time Quotes
Realtime quote and/or trade prices are not sourced from all markets
Today's Change-0.31(2.44%)
Bid (Size)$12.41 (100)
Ask (Size)$12.44 (100)
Day Low / High$12.26 - 12.93
Volume267.1 K

View Pharmaceuticals: Other IndustryPeer Comparison as of 01/23/2019


Ironwood Pharmaceuticals Inc ( NASDAQ )

Price: $12.41
Change: -0.31 (2.44%)
Volume: 267.1 K
12:24PM ET 1/23/2019

Medicines Co ( NASDAQ )

Price: $19.24
Change: -0.47 (2.38%)
Volume: 709.7 K
12:23PM ET 1/23/2019

Zogenix Inc ( NASDAQ )

Price: $41.13
Change: -1.27 (3.00%)
Volume: 130.7 K
12:21PM ET 1/23/2019

Innoviva Inc ( NASDAQ )

Price: $19.52
Change: -0.01 (0.05%)
Volume: 137.9 K
12:24PM ET 1/23/2019

Pacira Pharmaceuticals Inc ( NASDAQ )

Price: $38.53
Change: -1.93 (4.77%)
Volume: 538.9 K
12:24PM ET 1/23/2019

Read more news Recent News

Sector Update: Health Care Stocks Resist Afternoon Sell-Off as Biotechs Add to Advance
3:43PM ET 1/15/2019 MT Newswires

Top Health Care Stocks JNJ +0.62% PFE +0.65% ABT +2.91% MRK +1.54% AMGN +1.03% Health care stocks still were outperforming most of the broader...

Sector Update: Health Care
3:34PM ET 1/15/2019 MT Newswires

Health care stocks still were outperforming most of the broader markets, including a more than 1.6% rise for the NYSE Health Care Index in recent trade....

Ironwood Pharma Shares Jump After Winning China Ok of Linzess for Treatment of Adults with IBS-C
2:17PM ET 1/15/2019 MT Newswires

Ironwood Pharmaceuticals (IRWD) shares rose as much as 9.6% in Tuesday trading after the US commercial biotechnology company said China's National Medical...

Ironwood Pharmaceuticals Names CEOs for Planned Business Separation; Shares Up Near 8%
1:57PM ET 1/04/2019 MT Newswires

Ironwood Pharmaceuticals (IRWD) said Friday that it has appointed AstraZeneca (AZN) executive Mark Mallon as CEO and a director, and Peter Hecht as CEO and...

Company Profile

Business DescriptionIronwood Pharmaceuticals, Inc. operates as commercial biotechnology company, which discovers, develops and commercializes differentiated medicines that improve patient's lives. Its products include linaclotide, a guanylate cyclase type-C agonist being developed for the treatment of patients with irritable bowel syndrome with constipation and chronic constipation; and lesinurad for the treatment of hyperuricemia associated with uncontrolled gout. The company was founded by Peter M. Hecht, Eric F. Summers, G. Todd Milne, Brian M. Cali, Joseph C. Cook, Jr. and Gina Bornino Miller on January 5, 1998 and is headquartered in Cambridge, MA. View company web site for more details
Address301 Binney Street
Cambridge, Massachusetts 02142
Number of Employees730
Recent SEC Filing01/11/20194
Chief Executive Officer & DirectorPeter M. Hecht
Chief Operating OfficerWilliam I. Huyett
CFO, CAO, Controller & SVP-FinanceGina R. Consylman
Senior VP-Preclinical, Research & DevelopmentBrian M. Cali

Company Highlights

Price Open$12.82
Previous Close$12.72
52 Week Range$9.07 - 21.20
Market Capitalization$1.7 B
Shares Outstanding140.1 M
SectorHealth Technology
IndustryPharmaceuticals: Other
Next Earnings Announcement02/21/2019

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$1.24
Beta vs. S&P 500N/A
Revenue$298.3 M
Net Profit Margin-82.15%
Return on Equity408.56%

Analyst Ratings as of 01/11/2019

Consensus RecommendationConsensus Icon
Powered by Factset